Option chain shows key data for BioCardia's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BioCardia.

BioCardia (NASDAQ:BCDA) Stock, Option Chain

BIOCARDIA INC

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

doctor-563429

News

BCDA

BioCardia shares are trading lower by 12% during Friday&#39;s session. The company announced the pricing of an upsized public offering.

Why BioCardia (BCDA) Stock Is Falling Today

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADSE

BNRG

DELL

DLTH

EKSO

ESTC

FCUV

LGMK

LUCY

LUNR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MRVL

PALT

ULTA

VTAK

XRTX

Why MongoDB Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Crude Oil 6- logo

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

Eurozone

AFRM

AILE

ENSC

Crude Oil Moves Higher; Dollar General Earnings Miss Estimates

BioCardia Inc

Health Care

Press Releases

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

General

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Legal

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Eterna Therapeutics

Evaxion Biotech A/S - American Depositary Share

Evaxion Biotech

Geovax Labs

HCW Biologics

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Kairos Pharma

Marker Therapeutics

MetaVia

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

Ocean Biomedical

PharmaCyte Biotech

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Spruce Biosciences

Turnstone Biologics

HC Wainwright & Co.

Comments

BioCardia

BioCardia (BCDA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga